10-K: Palatin Technologies Reports Fiscal Year 2024 Results, Cites Going Concern Uncertainty

Palatin Technologies reports a net loss of $29.7 million for fiscal year 2024 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Palatin Technologies, a biopharmaceutical company, reported a net loss of $29.7 million for the fiscal year ended June 30, 2024, compared to a net loss of $24.0 million for the previous year.
• The company's accumulated deficit reached $441.8 million as of June 30, 2024.
• Palatin sold its Vyleesi product to Cosette in December 2023, potentially receiving up to $159 million in milestone payments, but does not anticipate significant payments in the near term.
• The company had cash, cash equivalents, and marketable securities of $9.5 million, with current liabilities of $9.7 million as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to the need for additional financing to complete clinical trials and development of product candidates.
• Palatin is focusing on developing melanocortin receptor system treatments for obesity and male sexual dysfunction, including combination therapies with bremelanotide.
• A Phase 2 clinical study for obesity treatment with bremelanotide and tirzepatide began in the second quarter of calendar year 2024.
• A pharmacokinetic study for a co-formulation of bremelanotide with a PDE5i for erectile dysfunction is targeted for the first quarter of calendar year 2025.
• Topline results from a Phase 3 clinical trial for PL9643 for dry eye disease were announced in the first quarter of calendar year 2024.
• A Phase 2 study for PL8177 for ulcerative colitis initiated patient enrollment in September 2022.
• A Phase 2 proof-of-concept study for diabetic nephropathy is ongoing, with topline results expected in the fourth quarter of calendar year 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a going concern warning, and the need for additional funding, which are major negative indicators. While there are some positive developments in clinical trials, the overall sentiment is negative due to the financial instability and uncertainty.

Positives

• The company initiated a Phase 2 clinical study for obesity treatment with bremelanotide and tirzepatide.
• A pharmacokinetic study for a co-formulation of bremelanotide with a PDE5i for erectile dysfunction is targeted for the first quarter of calendar year 2025.
• Topline results from a Phase 3 clinical trial for PL9643 for dry eye disease were announced.
• A Phase 2 study for PL8177 for ulcerative colitis initiated patient enrollment in September 2022.
• The company is actively engaged in discussions with potential partners and licensees for ocular conditions.

Negatives

• The company reported a net loss of $29.7 million for fiscal year 2024.
• The company's accumulated deficit reached $441.8 million as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has limited operating history upon which to base an investment decision.
• The company will need additional funding, which may not be available on acceptable terms.

Risks

• The company's management has determined that there is substantial doubt about its ability to continue as a going concern.
• The company has a history of substantial net losses and expects to incur losses for the foreseeable future.
• The company will need additional funding, which may not be available on acceptable terms, or at all.
• Clinical trials for product candidates may be prolonged or delayed, impacting commercialization timelines.
• Product candidates may not achieve market acceptance even if they receive regulatory approval.
• Side effects from product candidates could lead to additional trials, labeling changes, or market withdrawal.
• The company's stock price is volatile and may fluctuate disproportionately to operating performance.
• The company may experience dilution from the conversion of preferred stock, exercise of options and warrants, and vesting of restricted stock units.
• The company is not in compliance with the continued listing standards of the NYSE American, which could lead to delisting.

Future Outlook

The company expects to incur significant expenses as it continues to develop its MCr product candidates and will need additional funding to complete required clinical trials and development programs. The company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses.

Management Comments

• Our management has determined that there is substantial doubt about our ability to continue as a going concern because of our need to raise significant additional financing to complete clinical trials and development of our product candidates.
• We intend to focus future efforts on our bremelanotide combination products MC1r product candidates, primarily for ocular indications.

Industry Context

The biopharmaceutical industry is characterized by extensive research efforts and rapid technological change. Palatin faces competition from numerous established products and technologies, including those from major pharmaceutical and biotechnology companies. The recent extensive use of GLP-1 receptor agonist drug products has significantly increased competition in the obesity market. There are a number of drugs in development for ulcerative colitis, including Janus kinase inhibitors, monoclonal antibodies specific for one or more immune system cytokine signaling molecules, FXR inhibitor, integrin inhibitors, S1P1 receptor modulators, anti-TL1A monoclonal antibodies, DHODH inhibitor, HIF-1a stabilizer, LANCL2 receptor modulator, and additional classes of immunomodulatory drugs.

Comparison to Industry Standards

• Palatin's financial results, particularly the substantial net losses and accumulated deficit, are not uncommon for early-stage biopharmaceutical companies focused on research and development.
• The company's reliance on external funding and the going concern warning are typical for companies in this sector that have not yet achieved commercial success.
• The development of melanocortin receptor agonists is a competitive area, with companies like Rhythm Pharmaceuticals already marketing products such as Imcivree for chronic weight management.
• The company's approach of combining bremelanotide with other agents like GLP-1 agonists and PDE5i inhibitors is a strategy to enhance efficacy and reduce side effects, which is a common practice in the pharmaceutical industry.
• The development of PL9643 for dry eye disease places Palatin in competition with companies like Allergan (Restasis) and Novartis (Xiidra), which have established products in this market.
• The development of PL8177 for ulcerative colitis puts Palatin in competition with companies developing various biologic drugs, including tumor necrosis factor inhibitors such as infliximab and adalimumab.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution from future capital raises.
• Employees may be affected by potential cost reductions, including decreased staffing levels.
• Customers and partners may be impacted by delays in product development and commercialization due to financial constraints.
• Creditors face increased risk due to the company's going concern status.

Next Steps

• The company plans to complete patient enrollment in the Phase 2 trial for bremelanotide and tirzepatide later in calendar year 2024, with topline data expected in the first half of calendar year 2025.
• The company plans to initiate Investigational New Drug (IND) enabling activities for a novel MC4r selective long-acting agonist later this year, and file an IND in the second half of calendar year 2025.
• The company anticipates commencing a Phase 3 clinical study for bremelanotide co-formulated with a PDE5i in the second half of calendar year 2025.
• The company expects topline results from the Phase 2 study in ulcerative colitis using oral PL8177 in the first half of calendar year 2025.
• The company expects topline results from the Phase 2 proof-of-concept study for diabetic nephropathy in the fourth quarter of calendar year 2024.

Key Dates

Keywords

biopharmaceutical, melanocortin receptor, bremelanotide, obesity, erectile dysfunction, dry eye disease, ulcerative colitis, clinical trials, regulatory approval, Vyleesi, going concern